Log in

MiMedx Group Stock Forecast, Price & News

-0.52 (-8.15 %)
(As of 10/23/2020 12:00 AM ET)
Today's Range
Now: $5.86
50-Day Range
MA: $6.46
52-Week Range
Now: $5.86
Volume242,793 shs
Average Volume225,021 shs
Market Capitalization$650.67 million
P/E RatioN/A
Dividend YieldN/A
MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Read More
MiMedx Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolOTCMKTS:MDXG



Sales & Book Value

Annual Sales$299.26 million
Book Value$0.31 per share


Net Income$-25,580,000.00


Market Cap$650.67 million
Next Earnings Date11/3/2020 (Estimated)
-0.52 (-8.15 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

MiMedx Group (OTCMKTS:MDXG) Frequently Asked Questions

How has MiMedx Group's stock been impacted by COVID-19 (Coronavirus)?

MiMedx Group's stock was trading at $5.45 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MDXG stock has increased by 7.5% and is now trading at $5.86.
View which stocks have been most impacted by COVID-19

When is MiMedx Group's next earnings date?

MiMedx Group is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for MiMedx Group

How were MiMedx Group's earnings last quarter?

MiMedx Group Inc (OTCMKTS:MDXG) posted its quarterly earnings results on Tuesday, August, 4th. The medical equipment provider reported ($0.08) EPS for the quarter. The medical equipment provider earned $53.65 million during the quarter. MiMedx Group had a negative net margin of 12.51% and a negative return on equity of 116.79%.
View MiMedx Group's earnings history

Who are some of MiMedx Group's key competitors?

What other stocks do shareholders of MiMedx Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MiMedx Group investors own include Hawkins (HWKN), Micron Technology (MU), CA (CA), Opko Health (OPK), Amarin (AMRN), NVIDIA (NVDA), Endologix (ELGX), Gilead Sciences (GILD), AbbVie (ABBV) and CVS Health (CVS).

Who are MiMedx Group's key executives?

MiMedx Group's management team includes the following people:
  • Ms. Alexandra O. Haden, Gen. Counsel and Sec. (Age 43)
  • Mr. David J. Coles, Interim Chief Exec. Officer (Age 53)
  • Mr. Edward J. Borkowski, Interim Chief Financial Officer (Age 60)
  • Dr. Thomas J. Koob, Chief Scientific Officer (Age 69)
  • Mr. Thornton A. Kuntz Jr., Sr. VP of Admin. (Age 64)

What is MiMedx Group's stock symbol?

MiMedx Group trades on the OTCMKTS under the ticker symbol "MDXG."

How do I buy shares of MiMedx Group?

Shares of MDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MiMedx Group's stock price today?

One share of MDXG stock can currently be purchased for approximately $5.86.

How big of a company is MiMedx Group?

MiMedx Group has a market capitalization of $650.67 million and generates $299.26 million in revenue each year.

What is MiMedx Group's official website?

The official website for MiMedx Group is www.mimedx.com.

How can I contact MiMedx Group?

MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The medical equipment provider can be reached via phone at 770-51-9100 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.